Gout and Hyperuricemia Full Dose Therapeutics Drive

Gout & Hyperuricemia | Full Dose | Therapeutics Drive A comprehensive, evidence-based review of gout and hyperuricemia designed for pharmacists. This is the 🧠 Full Dose (40–60 min) episode of the Therapeutics Drive podcast by PharmaAnywhere. This is part of the Therapeutics Drive podcast — Clinical Learning for Pharmacists on the Go. Designed for community pharmacists, hospital pharmacists, pharmacy interns, and pharmacy students worldwide, this episode combines international evidence with practical Australian Therapeutic Guidelines (eTG) and PBS considerations where appropriate. In this episode, you'll learn: • Pathophysiology of hyperuricemia and gout • Risk factors and disease progression • Clinical presentation and diagnosis • Acute gout management: NSAIDs Colchicine (Colgout®) Corticosteroids • Urate-lowering therapy: Allopurinol (Zyloprim®) Febuxostat (Adenuric®) Treatment targets and dose titration • Flare prophylaxis during urate-lowering therapy initiation • Monitoring treatment response and serum uric acid targets • Lifestyle modification and patient counselling • Common prescribing pitfalls and medication safety • Practical community pharmacy interventions and clinical pearls Whether you're refreshing your knowledge or preparing for exams, this episode provides practical, guideline-based information to support everyday pharmacy practice. Looking for a quicker revision? 👉 Watch the ⚡ Quick Dose version for a concise, high-yield overview of the key concepts. REFERENCES (Vancouver Style) • Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364(5):443-452. • Richette P, Doherty M, Pascual E, et al. 2018 European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79:31-38. • Zhang W, Doherty M, Bardin T, et al. EULAR evidence-based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. • Hui M, Carr A, Cameron S, et al. British Society for Rheumatology guideline for the management of gout. Rheumatology. 2017;56(7):1056-1059. • FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020:1-17. • Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. • Qaseem A, McLean RM, Starkey M, et al. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):52-57. • Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68. • Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey 2007-2016. Arthritis Rheumatol. 2019;71(6):991-999. doi:10.1002/art.40807. • Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective—a review. J Adv Res. 2017;8(5):495-511. • Shields GE, Beard SM. A systematic review of the economic and humanistic burden of gout. PharmacoEconomics. 2015;33(10):1029-1047. • Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis. 2020;79(2):276-284. • Globeniewski J, Keenan RT. Moving the needle: improving the care of the gout patient. Rheumatol Ther. 2019;6(2):179-193. • Gaubert M, Marlinge M, Alessandrini M, et al. Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome. Purinergic Signal. 2018;14(2):191-199. • Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. • Chen JH, Lan JL, Cheng CF, et al. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694-1701. • Gao L, Wang B, Pan Y, et al. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic review and meta-analysis. Clin Cardiol. 2021;44:907-916. • MacKenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396:1745-1757. • Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052.